Get started

Financials · KURA

Kura Oncology Inc. (KURA) financials

For the twelve months ended Jun 30, 2026, Kura Oncology Inc. reported $77.22M of revenue and -$296.77M of net income.

Revenue, TTM
$77.22M
Net income, TTM
-$296.77M
Net margin
-384.3%
Free cash flow, TTM
-$117.43M
EPS, diluted, TTM
-$3.37
Cash
$70.24M
Total debt
$9.79M
P/S
8.72
Market cap
$673.4M
Annual revenue$67.48M
FY2023FY2025
Annual net income-$278.67M
FY2016FY2025
Annual free cash flow-$70.70M
FY2020FY2025

KURA revenue and earnings growth

KURA revenueQ2 2026$20.87M

Quarter YoY
+36.5%
QoQ
+14.3%
FY YoY
+25.2%

KURA revenue was $20.87M in fiscal Q2 2026 (ended Jun 30, 2026), up 36.5% from a year earlier and up 14.3% from the prior quarter. For the full fiscal 2025 it was $67.48M, up 25.2% from fiscal 2024.

KURA net incomeQ2 2026-$68.33M

KURA net income was -$68.33M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$66.12M a year earlier. For the full fiscal 2025 it was -$278.67M, compared with -$173.98M in fiscal 2024.

KURA EPSQ2 2026-$0.77

KURA diluted EPS was -$0.77 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.75 a year earlier. For the full fiscal 2025 it was -$3.18, compared with -$2.02 in fiscal 2024.

KURA free cash flowQ2 2026-$63.20M

KURA free cash flow was -$63.20M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$30.23M a year earlier. For the full fiscal 2025 it was -$70.70M, compared with $133.84M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$67.48M$53.88M$0-------
Research and development$251.07M$169.97M$115.23M$92.81M$84.72M$60.40M$47.83M$46.79M$26.43M-
Selling, general and admin$119.98M$77.11M$50.57M$47.05M$46.54M$31.50M$19.65M$16.10M$9.65M-
Operating income-$303.63M-$193.19M-$165.80M-$139.87M------
Interest expense$1.51M$1.62M$1.55M$229.0K$414.0K$578.0K$580.0K$970.0K$888.0K$577.0K
Pre-tax income-$278.37M-$171.97M-$152.63M-$135.84M------
Income tax$297.0K$2.02M$0$0$0$0$0$0$0$0
Net income-$278.67M-$173.98M-$152.63M-$135.84M-$130.47M-$89.63M-$63.14M-$60.45M-$35.43M-$27.56M
EPS, basic-$3.18-$2.02-$2.08-$2.03-$1.97-$1.69-$1.51-$1.72-$1.52-$1.47
EPS, diluted-$3.18-$2.02-$2.08-$2.03-$1.97-$1.69-$1.51-$1.72-$1.52-$1.47
Diluted shares87.7M86.2M73.2M67.0M66.4M53.1M41.9M35.2M23.2M18.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$149.10M$224.46M$37.32M$51.80M$90.67M$325.49M$26.14M$16.12M$11.43M$9.72M
Receivables$8.80M$2.06M--------
Inventory$413.0K$0--------
Current assets$708.66M$744.83M$432.48M$446.43M$522.29M$637.29M$239.60M$181.20M$94.64M$68.81M
Total assets$738.36M$760.16M$448.94M$456.31M$534.05M$647.21M$241.97M$182.38M$95.85M$69.82M
Current liabilities$116.97M$78.71M$35.26M$24.06M$22.45M$26.02M$15.56M$13.62M$10.03M$5.45M
Short-term debt$0$2.61M---$3.00M$250.0K-$1.53M-
Long-term debt$9.71M$6.92M$9.33M$9.16M-$4.25M$7.25M$7.50M$5.57M$7.32M
Total debt$9.71M$9.52M$9.33M$9.16M-$7.25M$7.50M$7.50M$7.10M$7.32M
Total liabilities$564.23M$346.52M$51.66M$36.03M$27.44M$36.31M$23.19M$21.39M$15.99M$12.95M
Shareholders' equity$174.13M$413.64M$397.27M$420.28M$506.61M$610.90M$218.78M$160.99M$79.86M$56.88M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$64.06M$134.32M-$124.82M-$110.06M-$104.55M-$69.83M-$54.76M-$48.66M-$28.44M-$25.35M
Capital expenditures$6.64M$472.0K$168.0K$626.0K$1.15M$2.17M----
Free cash flow-$70.70M$133.84M-$124.99M-$110.69M-$105.70M-$72.00M----
Investing cash flow-$13.10M-$101.59M$15.56M$32.63M-$126.83M-$99.94M-$46.33M-$79.30M-$23.42M$12.18M
Financing cash flow$1.79M$154.42M$94.78M$38.56M-$3.44M$469.33M$111.10M$132.64M$53.57M$7.45M
Stock-based compensation$37.11M$33.90M$28.08M$26.32M$23.58M$12.81M$9.41M$8.65M$4.54M$2.09M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY25.2%---------
Operating margin-449.9%-358.5%--------
Net margin-412.9%-322.9%--------
Free cash flow margin-104.8%248.4%--------
Return on equity-160.0%-42.1%-38.4%-32.3%-25.8%-14.7%-28.9%-37.5%-44.4%-48.5%
Return on assets-37.7%-22.9%-34.0%-29.8%-24.4%-13.8%-26.1%-33.1%-37.0%-39.5%
Current ratio6.069.4612.2618.5623.2624.4915.3913.319.4312.62
Debt to equity0.060.020.020.02-0.010.030.050.090.13

Source: XBRL data Kura Oncology Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KURA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KURA$77.22M--$296.77M-384.3%$673.4M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

KURA FAQ

8 questions
  • What is KURA revenue?
    Kura Oncology Inc. (KURA) reported $77.22M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $67.48M.
  • Is KURA profitable?
    No. Kura Oncology Inc. reported a net loss of $296.77M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does KURA have?
    Kura Oncology Inc. reported $70.24M in cash and cash equivalents and $9.79M of debt on its most recent balance sheet in SEC filings.
  • How fast is KURA revenue growing?
    Kura Oncology Inc.'s revenue changed +25.2% in fiscal 2025, to $67.48M.
  • What is KURA free cash flow?
    Kura Oncology Inc. generated -$117.43M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$111.76M less capital expenditures.
  • What is KURA earnings per share?
    Diluted earnings per share were -$3.37 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KURA last report financial results?
    The latest statements here come from Kura Oncology Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this KURA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Kura Oncology Inc. files with the SEC. It is provided for information only and is not investment advice.